MedTrace Logo

In-hospital Cardiac Arrest - Dynamics and State Transitions

NCT00920244 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 285

Last updated 2018-09-05

No results posted yet for this study

Summary

The purpose of this study is to analyse transitions in cardiac rhythm and hemodynamic variables during resuscitation of patients with in-hospital cardiac arrest.

Conditions

  • Heart Arrest
  • Death, Sudden, Cardiac

Interventions

PROCEDURE

Cardiopulmonary resuscitation (CPR)

CPR is performed according to international and national guidelines on all patients.

DRUG

Epinephrine

According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.

DRUG

Atropine

According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency \< 60 beat/min.

DRUG

Amiodarone

According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.

DEVICE

External defibrillator

According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.

Sponsors & Collaborators

  • Norwegian Air Ambulance Foundation

    collaborator OTHER

  • Norwegian University of Science and Technology

    collaborator OTHER

  • St. Olavs Hospital

    lead OTHER

Principal Investigators

  • Eirik Skogvoll, MD, PhD · St. Olavs Hospital

  • Trond Nordseth, MD · St. Olavs Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920244 on ClinicalTrials.gov